Haleon is trading 13.25% down at $8.68 after lowering its 2026 organic revenue growth outlook to around 2.5%, from 3%–5%.

  • Its October 29 update reported third-quarter growth of 2.6%, below expectations, as weaker cough, cold and flu demand reduced North American orders.
  • China import classification changes also weighed on performance. The company update and Reuters reporting link the downgrade to weak trading and the sharp share decline.